Context Therapeutics (NASDAQ:CNTX – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.7% of Context Therapeutics shares are held by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Context Therapeutics and CytomX Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Context Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| CytomX Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
Risk and Volatility
Context Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
Profitability
This table compares Context Therapeutics and CytomX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Context Therapeutics | N/A | -115.50% | -97.04% |
| CytomX Therapeutics | -0.56% | N/A | -0.26% |
Earnings and Valuation
This table compares Context Therapeutics and CytomX Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Context Therapeutics | N/A | N/A | -$23.96 million | ($1.50) | -0.92 |
| CytomX Therapeutics | $101.21 million | 1.07 | -$570,000.00 | ($0.02) | -79.96 |
CytomX Therapeutics has higher revenue and earnings than Context Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
CytomX Therapeutics beats Context Therapeutics on 7 of the 13 factors compared between the two stocks.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
